Arctigenin antagonizes mineralocorticoid receptor to inhibit the transcription of Na/K-ATPase

Journal of Receptors and Signal Transduction

Volumn 36, Issue 2, 2016, Pages 181-188

  Cheng, Ye ^a   Zhou, Meili ^b   Wang, Yan ^a  

^a Department of Cardiovascular Surgery   (China)

^b Second Hospital of Xiamen   (China)

Author keywords

Arctigenin; hypertension; mineralocorticoid receptor; Na K ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA GALACTOSIDASE; ARCTIGENIN; MESSENGER RNA; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; FURAN DERIVATIVE; LIGNAN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LYSATE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; ENZYME INHIBITION; ESCHERICHIA COLI; IC50; NONHUMAN; PHOTOCHEMICAL QUENCHING; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; SURFACE PLASMON RESONANCE; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; YEAST CELL; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; HYPERTENSION; PATHOLOGY;

ANIMALS; FURANS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; HYPERTENSION; LIGNANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; SODIUM-POTASSIUM-EXCHANGING ATPASE; SURFACE PLASMON RESONANCE; TRANSCRIPTIONAL ACTIVATION;

EID: 84956809880     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2015.1075039     Document Type: Article

References (20)

1. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 2000;101:329-35.
2. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001;104:545-56.
3. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005;186:1-20.
4. Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013;31:2094-102.
5. Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of lowdose spironolactone on resistant hypertension. J Am Soc Hypertens 2010;4:290-4.
6. Kolla V, Robertson NM, Litwack G. Identification of a mineralocorticoid/glucocorticoid response element in the human Na/K ATPase alpha1 gene promoter. Biochem Biophys Res Commun 1999;266:5-14.
7. Huyet J, Pinon GM, Fay MR, et al. Structural determinants of ligand binding to the mineralocorticoid receptor. Mol Cell Endocrinol 2012;350:87-95.
8. Derfoul A, Robertson NM, Lingrel JB, et al. Regulation of the human Na/K-ATPase beta1 gene promoter by mineralocorticoid and glucocorticoid receptors. J Biol Chem 1998;273:20702-11.
9. Kopec W, Loubet B, Poulsen H, Khandelia H. Molecular mechanism of Na(+), K(+)-ATPase malfunction in mutations characteristic of adrenal hypertension. Biochemistry 2014;53:746-54.
10. Schmitz B, Nedele J, Guske K, et al. Soluble adenylyl cyclase in vascular endothelium: gene expression control of epithelial sodium channel-alpha, Na+/K+-ATPase-alpha/beta, and mineralocorticoid receptor. Hypertension 2014;63:753-61.
11. Zhao F, Wang L, Liu K. In vitro anti-inflammatory effects of Arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. J Ethnopharmacol 2009;122:457-62.
12. Xu Z, Wang X, Zhou M, et al. The antidiabetic activity of total lignan from Fructus Arctii against alloxan-induced diabetes in mice and rats. Phytother Res 2008;22:97-101.
13. Cho MK, Jang YP, Kim YC, Kim SG. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition. Int Immunopharmacol 2004;4:1419-29.
14. Awale S, Lu J, Kalauni SK, et al. Identification of Arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res 2006;66:1751-7.
15. Zhu Z, Yan J, Jiang W, et al. Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid production and clearance. J Neurosci 2013;33: 13138-49.
16. Shen X, Tomoo K, Uchiyama S, et al. Structural and thermodynamic behavior of eukaryotic initiation factor 4E in supramolecular formation with 4E-binding protein 1 and mRNA cap analogue, studied by spectroscopic methods. Chem Pharm Bull (Tokyo) 2001;49:1299-303.
17. Ikeda U, Hyman R, Smith TW, Medford RM. Aldosteronemediated regulation of Na+, K(+)-ATPase gene expression in adult and neonatal rat cardiocytes. J Biol Chem 1991;266: 12058-66.
18. Skou JC, Esmann M. The Na, K-ATPase. J Bioenerg Biomembr 1992;24:249-61.
19. Funder JW. The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. Expert Opin Investig Drugs 2003; 12:1963-9.
20. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.